These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33619822)

  • 1. Prognostic value of intraductal carcinoma for adjuvant radiotherapy candidates after radical prostatectomy.
    Karakoc S; Celik S; Kaya N; Bozkurt O; Ellidokuz H; Tuna B; Yorukoglu K; Mungan MU
    Int J Clin Pract; 2021 Jun; 75(6):e14099. PubMed ID: 33619822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
    Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
    Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
    Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
    Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.
    Trinh VQ; Sirois J; Benzerdjeb N; Mansoori BK; Grosset AA; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Ladouceur M; Fradet Y; Saad F; Trudel D
    Prostate; 2018 Jul; 78(10):697-706. PubMed ID: 29603326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of the Intraductal Carcinoma of the Prostate on the Short-Term Oncological Outcomes.
    Kalemci S; Kizilay F; Simsir A; Emre Ergun K; Kose T
    Arch Esp Urol; 2022 Jun; 75(5):405-409. PubMed ID: 35983810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
    Kimura K; Tsuzuki T; Kato M; Saito AM; Sassa N; Ishida R; Hirabayashi H; Yoshino Y; Hattori R; Gotoh M
    Prostate; 2014 May; 74(6):680-7. PubMed ID: 24481730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
    Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
    Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic parameter for high risk prostate cancer patients at initial presentation.
    Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
    Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
    Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients.
    Jeyapala R; Kamdar S; Olkhov-Mitsel E; Zlotta A; Fleshner N; Visakorpi T; van der Kwast T; Bapat B
    Clin Genitourin Cancer; 2022 Jun; 20(3):e217-e226. PubMed ID: 35151601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.